lestaurtinib has been researched along with Leukemia, Myeloid in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, A; Lo-Coco, F; Löwenberg, B; Sanz, M | 1 |
| Friedman, AD; Small, D; Zheng, R | 1 |
| Allebach, J; Beran, M; Berg, K; Dauses, T; Giles, F; Kantarjian, H; Levis, M; Murphy, KM; Small, D; Smith, BD | 1 |
| Levis, M; Pham, R; Small, D; Smith, BD | 1 |
| Allebach, J; Brown, P; Chen, P; Kim, KT; Levis, M; Small, D | 1 |
| Naito, K; Ohnishi, K | 1 |
| Agrawal, S; Burnett, AK; Chopra, R; Clark, R; Kell, WJ; Knapper, S; Levis, MJ; Littlewood, T; Small, D | 1 |
| Austin, SJ; Burnett, AK; Gilkes, AF; Knapper, S; Mills, KI; Walsh, V | 1 |
| Kim, KT; Levis, M; Small, D | 1 |
2 review(s) available for lestaurtinib and Leukemia, Myeloid
| Article | Year |
|---|---|
FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Topics: Acute Disease; Animals; Carbazoles; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid; Molecular Structure; Mutation; Staurosporine | 2009 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
2 trial(s) available for lestaurtinib and Leukemia, Myeloid
| Article | Year |
|---|---|
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Carbazoles; DNA Mutational Analysis; Drug Monitoring; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Male; Middle Aged; Mutation; Phosphorylation; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Remission Induction; Salvage Therapy; Treatment Outcome | 2004 |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Carbazoles; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Male; Treatment Outcome | 2006 |
5 other study(ies) available for lestaurtinib and Leukemia, Myeloid
| Article | Year |
|---|---|
Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
Topics: Animals; Apoptosis; Carbazoles; Cell Differentiation; Cell Division; Cell Line; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Mice; Mutation; Myeloid Cells; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tandem Repeat Sequences; Transfection | 2002 |
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Indoles; Leukemia, Myeloid; Mice; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2004 |
FLT3/ITD mutation signaling includes suppression of SHP-1.
Topics: Acute Disease; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; fms-Like Tyrosine Kinase 3; Furans; Humans; Hydrolysis; Indoles; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mutation; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Vanadates | 2005 |
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
Topics: Acute Disease; Adolescent; Adult; Aged; Apoptosis; Blast Crisis; Carbazoles; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Male; Middle Aged; Mutation; Protein Kinase C; Protein-Tyrosine Kinases; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2006 |
Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Topics: Acute Disease; Apoptosis; bcl-Associated Death Protein; Carbazoles; Cell Proliferation; Cell Survival; Cells, Cultured; fms-Like Tyrosine Kinase 3; Furans; Humans; Immunoprecipitation; Indoles; Leukemia, Myeloid; Mutation; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-pim-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transfection | 2006 |